WE SELL NOTHING✳EVERY CLAIM → A PRIMARY SOURCE✳UNKNOWN IS A REAL ANSWER✳NO PRODUCTS · NO PROTOCOLS · NO VENDORS✳WE SELL NOTHING✳
← All issues
Issue No. 03 · Milestone decoder

The word after Phase 3 is not “approved.”

CagriSema, retatrutide, and mazdutide can all have serious clinical evidence without being the same molecule, reaching the same milestone, or validating anything sold online.

PepCurrent Editorial Desk · reviewed July 18, 2026 · 8 min read
The 90-second version

A phase 3 result can be an important clinical milestone. It is not an FDA application, an FDA review, approved labeling, or proof that a separately sold vial contains the studied product. Those are four different questions.

1. TrialDid an identified intervention produce a result under defined study conditions?
2. ApplicationDid a sponsor submit a product and evidence package for FDA review?
3. ApprovalDid FDA approve that specific product, labeling, and use?
4. IdentityIs the product in front of you actually the product that was studied or approved?

Late-stage is meaningful. It is not a synonym.

The internet often treats “phase 3” as the final scene before approval and then skips the scene entirely. But phase 3 describes a stage of clinical research, not a regulatory verdict. Results can be positive, mixed, incomplete, or interpreted differently after a full application review.

Approval also belongs to a product—not a word. FDA evaluates a defined formulation, manufacturer, manufacturing process, labeling, and proposed use. That is why even an approved ingredient name cannot authenticate a different vial.

Three programs, three different records

CagriSema

REDEFINE 1 randomized 3,417 adults without diabetes. At week 68, estimated mean body-weight change was −20.4% with coadministered cagrilintide and semaglutide and −3.0% with placebo. That is a large published phase 3 result—not FDA approval.

Retatrutide

Retatrutide has published phase 2 evidence and a major phase 3 program. Trial completion and sponsor-reported results do not become approved labeling until FDA completes its own review.

Mazdutide

GLORY-1 randomized 610 adults in China. At week 48, mean body-weight change was −11.00% and −14.01% in the two mazdutide groups and +0.30% with placebo. The study does not create a U.S. FDA approval.

The invisible leap is usually product identity

A trial can answer whether its intervention changed an outcome. It cannot tell you what is inside a product that was not part of the trial. Matching names do not establish chemical form, concentration, sterility, formulation, stability, storage history, or manufacturer.

FDA warning letters have described cagrilintide, mazdutide, retatrutide, and related products offered online in the United States as unapproved new drugs. That enforcement record is not evidence that every product is contaminated. It is evidence that a “research use only” label and a familiar molecule name do not create approval.

The translation error: “A defined study product worked in a randomized trial” becomes “this vial is the same product and is basically approved.” The second sentence adds identity and regulatory claims the trial never tested.

The safest status sentence has a date

Investigational-product status can change. A responsible reference page therefore says what is known as of a specific review date, separates published evidence from sponsor announcements, and watches FDA records for an actual application or approval action.

That may sound less exciting than a launch countdown. It is also more useful: a reader can see exactly which milestone occurred and which one did not.

What PepCurrent will update

  • A peer-reviewed trial publication changes the evidence record.
  • A ClinicalTrials.gov update changes the study-status record.
  • An FDA filing or review changes the regulatory-process record.
  • An FDA approval changes the product-and-labeling record.
  • None of those events, by itself, authenticates an unrelated product sold under the same name.

Editorial boundary: This issue explains public study and regulatory milestones. It does not rank treatments, recommend use, compare doses, identify sellers, or assess an individual product.

Independent review passed July 18, 2026. Read the source log →